

Bernhard Hellmich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6230501/publications.pdf>

Version: 2024-02-01

42
papers

6,966
citations

218677

26
h-index

155660

55
g-index

66
all docs

66
docs citations

66
times ranked

4608
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 222-227.	0.9	1,041
2	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1583-1594.	0.9	940
3	EULAR recommendations for the management of primary small and medium vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 310-317.	0.9	889
4	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 19-30.	0.9	667
5	EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 318-323.	0.9	596
6	EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 605-617.	0.9	524
7	Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1004-1010.	0.9	343
8	Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. <i>Nature Reviews Rheumatology</i> , 2017, 13, 683-692.	8.0	302
9	A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churgâ€“Strauss, EGPA): monocentric experiences in 150 patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1011-1017.	0.9	226
10	Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. <i>Rheumatology</i> , 2007, 46, 1087-1091.	1.9	196
11	Targeting Interleukin-5 in Refractory and Relapsing Churgâ€“Strauss Syndrome. <i>Annals of Internal Medicine</i> , 2011, 155, 341.	3.9	180
12	Proinflammatory Cytokines and Autoimmunity in Churg-Strauss Syndrome. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 121-131.	3.8	118
13	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis: A Randomized Controlled Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 952-963.	5.6	82
14	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	5.6	78
15	Evaluation of automated multi-parametric indirect immunofluorescence assays to detect anti-neutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). <i>Autoimmunity Reviews</i> , 2016, 15, 736-741.	5.8	56
16	Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. <i>RMD Open</i> , 2019, 5, e001020.	3.8	56
17	Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. <i>RMD Open</i> , 2019, 5, e001003.	3.8	52
18	Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 653-661.	0.9	49

#	ARTICLE	IF	CITATIONS
19	Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opinion on Pharmacotherapy, 2004, 5, 25-35.	1.8	45
20	Churg Strauss syndrome--successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clinical and Experimental Rheumatology, 2004, 22, S52-61.	0.8	45
21	Update on the pathogenesis of Churg-Strauss syndrome. Clinical and Experimental Rheumatology, 2003, 21, S69-77.	0.8	43
22	Intravenous Immunoglobulin Therapy in Vasculitis: Speculation or Evidence?. Clinical Reviews in Allergy and Immunology, 2005, 29, 237-246.	6.5	41
23	International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1360-1372.	5.6	36
24	Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study. Clinical and Experimental Rheumatology, 2010, 28, 24-30.	0.8	34
25	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open, 2017, 3, e000449.	3.8	23
26	New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study. Rheumatology, 2021, 60, 4868-4873.	1.9	23
27	Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Rheumatology, 2021, 60, 4355-4360.	1.9	21
28	Treatment of Giant Cell Arteritis and Takayasu Arteritis--Current and Future. Current Rheumatology Reports, 2020, 22, 84.	4.7	19
29	Usefulness of vasculitis biomarkers in the era of the personalized medicine. Autoimmunity Reviews, 2020, 19, 102514.	5.8	13
30	A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clinical and Experimental Rheumatology, 2008, 26, S35-40.	0.8	13
31	Individual values of antineutrophil cytoplasmic antibodies do not correspond between antigen-specific assays. Clinical Chemistry and Laboratory Medicine, 2018, 56, e39-e42.	2.3	12
32	Two Immunocompromised Patients With Diffuse Alveolar Hemorrhage as a Complication of Severe Coronavirus Disease 2019. Chest, 2020, 158, e215-e219.	0.8	12
33	Anti-neutrophil cytoplasm antibodies (ANCA): Recent methodological advances--Lead to new consensus recommendations for ANCA detection. Journal of Immunological Methods, 2018, 456, 1-6.	1.4	10
34	Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature. Autoimmunity Reviews, 2022, 21, 103034.	5.8	8
35	GCA management guidelines -- vive la différence?. Nature Reviews Rheumatology, 2021, 17, 649-650.	8.0	4
36	O27. ANCA STATUS IN EOSINOPHIL GRANULOMATOSIS WITH POLYANGIITIS: A MONOCENTRIC COHORT ANALYSIS OF MANIFESTATIONS AND RELAPSES OF ANCA-POSITIVE AND ANCA-NEGATIVE PATIENTS. Rheumatology, 2019, 58, .	1.9	2

#	ARTICLE	IF	CITATIONS
37	THU0286â€¦MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS. , 2019, , .		2
38	Evaluation of PR3- and MPO-ANCA line and dot immunoassays in ANCA-associated vasculitis. Rheumatology, 2021, 60, 4390-4394.	1.9	2
39	Utility of serum complement factors C3 and C4 as biomarkers during therapeutic management of giant cell arteritis. Scandinavian Journal of Rheumatology, 2023, 52, 276-282.	1.1	2
40	FRIO284â€¦RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS: EVIDENCE TO GUIDE THE MANAGEMENT OF GIANT CELL ARTERITIS. , 2019, , .		1
41	AB0370â€¦UTILITY OF CRP AND ESR IN THE DIAGNOSIS OF GIANT CELL ARTERITIS RELAPSE IN A PHASE 2 TRIAL OF MAVRILIMUMAB. Annals of the Rheumatic Diseases, 2021, 80, 1211-1212.	0.9	1
42	Response to: â€˜Error in the dosage of methotrexate in the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitisâ€™™ by Scheicht. Annals of the Rheumatic Diseases, 2022, 81, e90-e90.	0.9	0